Advances in the management of peritoneal mesothelioma
Advances in the management of peritoneal mesothelioma作者机构：Division of Surgical Oncology Department of Surgery Virginia Commonwealth University School of Medicine and Massey Cancer Center Richmond VA 23298-0011 United States
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2014年第20卷第33期
页 面：11700-11712页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by United States National Institute of Health(to Kazuaki Takabe),No.R01CA160688 Investigator Initiated Research Grant(to Susan G Komen),No.IIR12222224
主 题：Peritoneal mesothelioma Mesothelioma Hyperthermic intraperitoneal chemotherapy Cytore-duction Sphingosine kinase Sphingosine-1-phosphate FTY720
摘 要：Malignant peritoneal mesothelioma(PM) is an infrequent disease which has historically been associated with a poor prognosis. Given its long latency period and non-specific symptomatology, a diagnosis of PM can be suggested by occupational exposure history, but ultimately relies heavily on imaging and diagnostic biopsy. Early treatment options including palliative operative debulking, intraperitoneal chemotherapy, and systemic chemotherapy have marginally improved the natural course of the disease with median survival being approximately one year. The advent of cytoreduction(CRS) with hyperthermic intraperitoneal chemotherapy(HIPEC) has dramatically improved survival outcomes with wide median survival estimates between 2.5 to 9 years; these studies however remain largely heterogeneous, with differing study populations, tumor biology, and specific treatment regimens. More recent investigations have explored extent of cytoreduction, repeated operative intervention, and choice of chemotherapy but have been unable to offer definitive conclusions. CRS and HIPEC remain morbid procedures with complication rates ranging between 30% to 46% in larger series. Ac-cordingly, an increasing interest in identifying molecular targets and developing targeted therapies is emerging. Among such novel targets is sphingosine kinase 1(SphK1) which regulates the production of sphingosine-1-phosphate, a biologically active lipid implicated in various cancers including malignant mesothelioma. The known action of specific SphK inhibitors may warrant further exploration in peritoneal disease.
维普期刊数据库